Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cost Effectiveness and Resource Allocation
Published in: Cost Effectiveness and Resource Allocation 1/2017

Open Access 01-12-2017 | Review

Cost-effectiveness analysis of malaria interventions using disability adjusted life years: a systematic review

Authors: Resign Gunda, Moses John Chimbari

Published in: Cost Effectiveness and Resource Allocation | Issue 1/2017

Login to get access

Abstract

Background

Malaria continues to be a public health problem despite past and on-going control efforts. For sustenance of control efforts to achieve the malaria elimination goal, it is important that the most cost-effective interventions are employed. This paper reviews studies on cost-effectiveness of malaria interventions using disability-adjusted life years.

Methods

A review of literature was conducted through a literature search of international peer-reviewed journals as well as grey literature. Searches were conducted through Medline (PubMed), EMBASE and Google Scholar search engines. The searches included articles published in English for the period from 1996 to 2016. The inclusion criteria for the study were type of malaria intervention, year of publication and cost-effectiveness ratio in terms of cost per DALY averted. We included 40 studies which specifically used the DALY metric in cost-effectiveness analysis (CEA) of malaria interventions.

Results

The majority of the reviewed studies (75%) were done using data from African settings with the majority of the interventions (60.0%) targeting all age categories. Interventions included case treatment, prophylaxis, vector control, insecticide treated nets, early detection, environmental management, diagnosis and educational programmes. Sulfadoxine–pyrimethamine was the most common drug of choice in malaria prophylaxis, while artemisinin-based combination therapies were the most common drugs for case treatment. Based on guidelines for CEA, most interventions proved cost-effective in terms of cost per DALYs averted for each intervention.

Conclusion

The DALY metric is a useful tool for determining the cost-effectiveness of malaria interventions. This paper demonstrates the importance of CEA in informing decisions made by policy makers.
Literature
1.
WHO. World malaria report. Geneva: WHO; 2015.
2.
Githeko AK, Ndegwa W. Predicting malaria epidemics in the Kenyan highlands using climate data: a tool for decision makers. Glob Chang Hum Health. 2001;2(1):54–63.CrossRef
3.
Goodman CA, Coleman PG, Mills AJ. Cost-effectiveness of malaria control in sub-Saharan Africa. Lancet. 1999;354(9176):378–85.CrossRefPubMed
4.
Evans DB, et al. Methods to assess the costs and health effects of interventions for improving health in developing countries. BMJ. 2005;331(7525):1137–40.CrossRefPubMedPubMedCentral
5.
6.
7.
Creese A, et al. Cost-effectiveness of HIV/AIDS interventions in Africa: a systematic review of the evidence. Lancet. 2002;359(9318):1635–43.CrossRefPubMed
8.
Lubell Y, et al. Cost-effectiveness of parenteral artesunate for treating children with severe malaria in sub-Saharan Africa. Bull World Health Organ. 2011;89(7):504–12.CrossRefPubMedPubMedCentral
9.
Bener A, et al. Measuring burden of diseases in a rapidly developing economy: state of Qatar. Glob J Health Sci. 2013;5(2):134–44.
10.
Murray CJL, Lopez A. The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. 1st ed. Cambridge: Harvard University Press; 1996.
11.
Murray CJ, Lopez AD, editors. The Global Burden of Disease. Havard School of Public Health: Geneva; 1998. p. 1–46.
12.
Donev D, Zaletel-Kragelj L, Bjegovic V, Burazeri G. Measuring the burden of disease: disability adjusted life year (daly). Methods and tools in public health. In: Zaletel-Kragelj L, Boţikov J, editors. A handbook for teachers, researchers and health professionals. Lage: Hans Jacobs Publishing Company; 2010.
13.
14.
Murray CJL, Lopez AD. Global health statistics: a compendium of incidence, prevalence and mortality estimates for over 200 conditions. 2nd ed. Cambridge: Harvard University Press; 1996.
15.
WHO. Making choices in health: WHO guide to cost-effectiveness analysis. In: Tan-Torres Edejer T, Baltussen R, Adam T, Hutubessy R, Acharya A, Evans DB, Murray DB, Murray CJL, editors. Geneva: WHO; 2003.
16.
Moher D, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Open Med. 2009;3(3):e123–30.PubMedPubMedCentral
17.
Edwards C. Cost-effectiveness analysis in practice. In: Hunter P, Cameron J, Jagals P, Pond K, editors. Valuing water, valuing livelihoods. London: IWA Publishing; 2011. p. 181–197.
18.
WHO. Investing in health research and development: report of the ad hoc committee on health research relating to future intervention options. Geneve: WHO; 1996.
19.
20.
GBD 2013 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990–2013: quantifying the epidemiological transition. Lancet. 2015;386(10009):2145–91.CrossRefPubMedCentral
21.
Pfeil J, Borrmann S, Tozan Y. Dihydroartemisinin–piperaquine vs. artemether–lumefantrine for first-line treatment of uncomplicated malaria in African children: a cost-effectiveness analysis. PLoS ONE. 2014;9(4):e95681.CrossRefPubMedPubMedCentral
22.
Buchanan J, et al. Cost-effectiveness of pre-referral antimalarial, antibacterial, and combined rectal formulations for severe febrile illness. PLoS ONE. 2010;5(12):e14446.CrossRefPubMedPubMedCentral
23.
Mori AT, et al. Cost-effectiveness of dihydroartemisinin–piperaquine compared with artemether–lumefantrine for treating uncomplicated malaria in children at a district hospital in Tanzania. Malar J. 2014;13:363.CrossRefPubMedPubMedCentral
24.
Tediosi F, et al. An approach to model the costs and effects of case management of Plasmodium falciparum malaria in Sub-Saharan Africa. Am J Trop Med Hyg. 2006;75(2 Suppl):90–103.CrossRefPubMed
25.
Tozan Y, et al. Prereferral rectal artesunate for treatment of severe childhood malaria: a cost-effectiveness analysis. Lancet. 2010;376(9756):1910–5.CrossRefPubMed
26.
Wolfe EB, et al. Cost-effectiveness of sulfadoxine–pyrimethamine for the prevention of malaria-associated low birth weight. Am J Trop Med Hyg. 2001;64(3–4):178–86.CrossRefPubMed
27.
Akhavan D, et al. Cost-effective malaria control in Brazil: cost-effectiveness of a malaria control program in the Amazon Basin of Brazil, 1988–1996. Soc Sci Med. 1999;49(10):1385–99.CrossRefPubMed
28.
Utzinger J, Tozan Y, Singer BH. Efficacy and cost-effectiveness of environmental management for malaria control. Trop Med Int Health. 2001;6(9):677–87.CrossRefPubMed
29.
30.
31.
Hutton G. Cost-effectiveness of malaria intermittent preventive treatment in infants (IPTi) in Mozambique and the United Republic of Tanzania. Bull World Health Organ. 2009;87(2):123–9.CrossRefPubMedPubMedCentral
32.
33.
Alonzo Gonzalez M, et al. Cost-effectiveness of iron supplementation and malaria chemoprophylaxis in the prevention of anaemia and malaria among Tanzanian infants. Bull World Health Organ. 2000;78(1):97–107.PubMedPubMedCentral
34.
Maire N, et al. Cost-effectiveness of the introduction of a pre-erythrocytic malaria vaccine into the expanded program on immunization in sub-Saharan Africa: analysis of uncertainties using a stochastic individual-based simulation model of Plasmodium falciparum malaria. Value Health. 2011;14(8):1028–38.CrossRefPubMed
35.
36.
Penny MA, et al. Public health impact and cost-effectiveness of the RTS, S/AS01 malaria vaccine: a systematic comparison of predictions from four mathematical models. Lancet. 2016;387(10016):367–75.CrossRefPubMedPubMedCentral
37.
Ross A, et al. Determinants of the cost-effectiveness of intermittent preventive treatment for malaria in infants and children. PLoS ONE. 2011;6(4):e18391.CrossRefPubMedPubMedCentral
38.
39.
40.
Seo MK, Baker P, Ngo KN. Cost-effectiveness analysis of vaccinating children in Malawi with RTS,S vaccines in comparison with long-lasting insecticide-treated nets. Malar J. 2014;13:66.CrossRefPubMedPubMedCentral
41.
42.
43.
Becker-Dreps SI, et al. Cost-effectiveness of adding bed net distribution for malaria prevention to antenatal services in Kinshasa, Democratic Republic of the Congo. Am J Trop Med Hyg. 2009;81(3):496–502.PubMed
44.
Briet OJ, Chitnis N. Effects of changing mosquito host searching behaviour on the cost effectiveness of a mass distribution of long-lasting, insecticidal nets: a modelling study. Malar J. 2013;12:215.CrossRefPubMedPubMedCentral
45.
Briet OJ, et al. Effects of pyrethroid resistance on the cost effectiveness of a mass distribution of long-lasting insecticidal nets: a modelling study. Malar J. 2013;12:77.CrossRefPubMedPubMedCentral
46.
Coleman PG, Goodman CA, Mills A. Rebound mortality and the cost-effectiveness of malaria control: potential impact of increased mortality in late childhood following the introduction of insecticide treated nets. Trop Med Int Health. 1999;4(3):175–86.CrossRefPubMed
47.
Kahn JG, et al. Integrated HIV testing, malaria, and diarrhea prevention campaign in Kenya: modeled health impact and cost-effectiveness. PLoS ONE. 2012;7(2):e31316.CrossRefPubMedPubMedCentral
48.
Mueller DH, et al. Cost-effectiveness analysis of insecticide-treated net distribution as part of the Togo Integrated Child Health Campaign. Malar J. 2008;7:73.CrossRefPubMedPubMedCentral
49.
50.
Utzinger J, et al. The economic payoffs of integrated malaria control in the Zambian copperbelt between 1930 and 1950. Trop Med Int Health. 2002;7(8):657–77.CrossRefPubMed
51.
Chen IT, et al. Cost-effectiveness analysis of malaria rapid diagnostic test incentive schemes for informal private healthcare providers in Myanmar. Malar J. 2015;14:55.CrossRefPubMedPubMedCentral
52.
Shillcutt S, et al. Cost-effectiveness of malaria diagnostic methods in sub-Saharan Africa in an era of combination therapy. Bull World Health Organ. 2008;86(2):101–10.CrossRefPubMed
53.
Goodman CA, et al. The cost-effectiveness of improving malaria home management: shopkeeper training in rural Kenya. Health Policy Plan. 2006;21(4):275–88.CrossRefPubMed
54.
Sun DW, et al. A cost-effectiveness analysis of Plasmodium falciparum malaria elimination in Hainan Province, 2002–2012. Am J Trop Med Hyg. 2015;93(6):1240–8.CrossRefPubMedPubMedCentral
55.
Pfeil J, et al. An economic evaluation of the posttreatment prophylactic effect of dihydroartemisinin–piperaquine versus artemether–lumefantrine for first-line treatment of Plasmodium falciparum malaria across different transmission settings in Africa. Am J Trop Med Hyg. 2015;93(5):961–6.CrossRefPubMedPubMedCentral
56.
Fernandes S, et al. Cost-effectiveness of two versus three or more doses of intermittent preventive treatment for malaria during pregnancy in sub-Saharan Africa: a modelling study of meta-analysis and cost data. Lancet Glob Health. 2015;3(3):e143–53.CrossRefPubMed
57.
58.
Sicuri E, et al. Economic evaluation of an alternative drug to sulfadoxine–pyrimethamine as intermittent preventive treatment of malaria in pregnancy. PLoS ONE. 2015;10(4):e0125072.CrossRefPubMedPubMedCentral
59.
Marseille E, et al. Thresholds for the cost-effectiveness of interventions: alternative approaches. Bull World Health Organ. 2015;93(2):118–24.CrossRefPubMed
Metadata
Title
Cost-effectiveness analysis of malaria interventions using disability adjusted life years: a systematic review
Authors
Resign Gunda
Moses John Chimbari
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Cost Effectiveness and Resource Allocation / Issue 1/2017
Electronic ISSN: 1478-7547
DOI
https://doi.org/10.1186/s12962-017-0072-9

Other articles of this Issue 1/2017

Cost Effectiveness and Resource Allocation 1/2017 Go to the issue

Research

Economic evaluation of participatory learning and action with women’s groups facilitated by Accredited Social Health Activists to improve birth outcomes in rural eastern India

Methodology

Disease control programme support costs: an update of WHO-CHOICE methodology, price databases and quantity assumptions

Research

Cost-effectiveness analysis of the national decentralization policy of antiretroviral treatment programme in Zambia

Research

Costs and savings associated with a pharmacists prescribing for minor ailments program in Saskatchewan

Methodology

Defining a staged-based process for economic and financial evaluations of mHealth programs

Research

Public engagement in setting healthcare priorities: a ranking exercise in Cyprus